| abstract |
The compounds of the formula (I): (see formula (1)) provide pharmacological agents that bind with the Peroxisome Proliferator Activated Receptors (PPARs). In accordance with the foregoing, the compounds of the present invention are useful for the treatment of conditions mediated by the activity of the PPAR receptor in mammals. These conditions include dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's diseases, skin disorders, respiratory diseases, ophthalmic disorders inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease, and conditions in which impaired glucose tolerance hyperglycemia, and insulin resistance, such as type-1 and type-11 diabetes, and Syndrome X are involved . |